The total return over the past 12 months is +95.23% vs. +16.94% for the S&P 500. So far it's up +61.51% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +95.23% | +73.43% | +30.25% | (1.73%) | +0.53% | N/A |
| Total Return CAGR | +95.23% | +73.43% | +30.25% | (1.73%) | +0.53% | N/A |
| Revenue CAGR | +9.28% | +10.48% | +8.67% | +13.29% | N/A | N/A |
| Net Income CAGR | N/A | N/A | (4.57%) | (8.19%) | N/A | N/A |
| EPS CAGR | N/A | N/A | (17.72%) | (12.75%) | N/A | N/A |
| Free Cash Flow CAGR | (68.34%) | (17.05%) | (14.46%) | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (42.81%) | +0.36% | (4.05%) | +12.48% | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Amneal Pharmaceuticals, Inc. (AMRX)
| Year | Start price | End price | AMRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $12.60 | $20.35 | +61.51% | +14.51% | +47.00% |
| 2025 | $7.92 | $12.60 | +59.09% | +17.72% | +41.37% |
| 2024 | $6.07 | $7.92 | +30.48% | +24.89% | +5.59% |
| 2023 | $1.99 | $6.07 | +205.03% | +26.19% | +178.84% |
| 2022 | $4.79 | $1.99 | (58.46%) | (18.17%) | (40.29%) |
| 2021 | $4.57 | $4.79 | +4.81% | +28.74% | (23.93%) |
| 2020 | $4.82 | $4.57 | (5.19%) | +18.37% | (23.56%) |
| 2019 | $13.53 | $4.82 | (64.38%) | +31.22% | (95.60%) |
| 2018 | $16.65 | $13.53 | (18.74%) | (4.56%) | (14.18%) |
| 2017 | $13.25 | $16.65 | +25.66% | +21.70% | +3.96% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
